KalVista Pharmaceuticals, Inc.
General ticker "KALV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $592.1M (TTM average)
KalVista Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 24.4%.
Estimated limits based on current volatility of 6.3%: low 13.78$, high 15.63$
Factors to consider:
- Earnings expected soon, date: 2025-12-11 bmo
- Total employees count: 150 (+27.1%) as of 2024
- Top business risk factors: Lack of profitability, High R&D costs, Funding dependency, Market competition, Regulatory and compliance
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-04-30 to 2027-04-30
- 2025-04-30 to 2026-04-30 estimated range: [6.98$, 16.22$]
- 2026-04-30 to 2027-04-30 estimated range: [5.16$, 12.54$]
Financial Metrics affecting the KALV estimates:
- Negative: with PPE of -3.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -24.04 <= 0.33
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.91 <= 3.41
- Positive: 18.93 < Shareholder equity ratio, % of 38.04 <= 41.86
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -100 <= -0.75
Short-term KALV quotes
Long-term KALV plot with estimates
Financial data
| YTD | 2023-04-30 | 2024-04-30 | 2025-04-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $110.87MM | $140.44MM | $188.00MM |
| Operating Income | $-110.87MM | $-140.44MM | $-188.00MM |
| Non-Operating Income | $17.96MM | $13.80MM | $7.94MM |
| Interest Expense | $0.00MM | $0.00MM | $5.79MM |
| R&D Expense | $80.28MM | $86.17MM | $71.71MM |
| Income(Loss) | $-92.91MM | $-126.64MM | $-180.05MM |
| Taxes | $0.00MM | $0.00MM | $3.39MM |
| Profit(Loss)* | $-92.91MM | $-126.64MM | $-183.44MM |
| Stockholders Equity | $161.03MM | $206.58MM | $95.39MM |
| Assets | $183.20MM | $235.40MM | $250.77MM |
| Operating Cash Flow | $-75.26MM | $-89.23MM | $-152.91MM |
| Capital expenditure | $1.20MM | $0.44MM | $0.43MM |
| Investing Cash Flow | $41.41MM | $-84.72MM | $91.02MM |
| Financing Cash Flow | $58.12MM | $150.71MM | $159.73MM |
| Earnings Per Share** | $-3.33 | $-3.44 | $-3.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.